DNTH

Company Overview — What Does Dianthus Therapeutics, Inc. /DE/ Do?

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Dianthus Therapeutics, Inc. /DE/ (DNTH) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jason Gardner and employs approximately 80 people. With a market capitalization of $4.5B, DNTH is one of the notable companies in the Healthcare sector.

Dianthus Therapeutics, Inc. /DE/ (DNTH) Stock Rating — Hold (April 2026)

As of April 2026, Dianthus Therapeutics, Inc. /DE/ receives a Hold rating with a composite score of 38.8/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.DNTH ranks #1,602 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Dianthus Therapeutics, Inc. /DE/ ranks #143 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DNTH Stock Price and 52-Week Range

Dianthus Therapeutics, Inc. /DE/ (DNTH) currently trades at $89.77. The stock lost $1.89 (2.1%) in the most recent trading session. The 52-week high for DNTH is $88.02, which means the stock is currently trading 2.0% from its annual peak. The 52-week low is $13.37, putting the stock 571.7% above its annual trough. Recent trading volume was 481K shares, suggesting relatively thin trading activity.

Is DNTH Overvalued or Undervalued? — Valuation Analysis

Dianthus Therapeutics, Inc. /DE/ (DNTH) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 9.25x, versus the sector average of 2.75x. The price-to-sales ratio is 1163.00x, compared to 1.66x for the average Healthcare stock.

At current multiples, Dianthus Therapeutics, Inc. /DE/ trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Dianthus Therapeutics, Inc. /DE/ Profitability — ROE, Margins, and Quality Score

Dianthus Therapeutics, Inc. /DE/ (DNTH) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -24.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -23.2% versus the sector average of -33.1%.

The operating margin is -8125.0% (sector: -66.1%). Net profit margin stands at -7342.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -78.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DNTH Debt, Balance Sheet, and Financial Health

Dianthus Therapeutics, Inc. /DE/ has a debt-to-equity ratio of 8.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 13.32x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $56M.

DNTH has a beta of 1.05, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Dianthus Therapeutics, Inc. /DE/ is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Dianthus Therapeutics, Inc. /DE/ Revenue and Earnings History — Quarterly Trend

In TTM 2026, Dianthus Therapeutics, Inc. /DE/ reported revenue of $4M and earnings per share (EPS) of $-4.20. Net income for the quarter was $-123M. Operating income came in at $-138M.

In FY 2025, Dianthus Therapeutics, Inc. /DE/ reported revenue of $2M and earnings per share (EPS) of $-4.20. Net income for the quarter was $-162M. Revenue grew -67.3% year-over-year compared to FY 2024. Operating income came in at $-178M.

In Q3 2025, Dianthus Therapeutics, Inc. /DE/ reported revenue of $396,000 and earnings per share (EPS) of $-0.97. Net income for the quarter was $-37M. Revenue grew -81.8% year-over-year compared to Q3 2024. Operating income came in at $-40M.

In Q2 2025, Dianthus Therapeutics, Inc. /DE/ reported revenue of $193,000 and earnings per share (EPS) of $-0.88. Net income for the quarter was $-32M. Revenue grew -89.6% year-over-year compared to Q2 2024. Operating income came in at $-35M.

Over the past 8 quarters, Dianthus Therapeutics, Inc. /DE/ has demonstrated a growth trajectory, with revenue expanding from $2M to $4M. Investors analyzing DNTH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DNTH Dividend Yield and Income Analysis

Dianthus Therapeutics, Inc. /DE/ (DNTH) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DNTH Momentum and Technical Analysis Profile

Dianthus Therapeutics, Inc. /DE/ (DNTH) has a momentum factor score of 77/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 12/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

DNTH vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Dianthus Therapeutics, Inc. /DE/ (DNTH) ranks #143 out of 838 stocks based on the Blank Capital composite score. This places DNTH in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DNTH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DNTH vs S&P 500 (SPY) comparison to assess how Dianthus Therapeutics, Inc. /DE/ stacks up against the broader market across all factor dimensions.

DNTH Next Earnings Date

No upcoming earnings date has been announced for Dianthus Therapeutics, Inc. /DE/ (DNTH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DNTH? — Investment Thesis Summary

Dianthus Therapeutics, Inc. /DE/ presents a balanced picture with arguments on both sides. The quality score of 21/100 flags below-average profitability. The value score of 29/100 indicates premium valuation. Price momentum is positive at 77/100, suggesting the trend favors buyers. High volatility (stability score 36/100) increases portfolio risk.

In summary, Dianthus Therapeutics, Inc. /DE/ (DNTH) earns a Hold rating with a composite score of 38.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DNTH stock.

Related Resources for DNTH Investors

Explore more research and tools: DNTH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DNTH head-to-head with peers: DNTH vs AZN, DNTH vs SLGL, DNTH vs VMD.